IL311468A - Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof - Google Patents
Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereofInfo
- Publication number
- IL311468A IL311468A IL311468A IL31146824A IL311468A IL 311468 A IL311468 A IL 311468A IL 311468 A IL311468 A IL 311468A IL 31146824 A IL31146824 A IL 31146824A IL 311468 A IL311468 A IL 311468A
- Authority
- IL
- Israel
- Prior art keywords
- insulin
- glucagon
- secreting
- cell population
- type
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims 74
- 102000004877 Insulin Human genes 0.000 title claims 37
- 108090001061 Insulin Proteins 0.000 title claims 37
- 229940125396 insulin Drugs 0.000 title claims 37
- 210000001511 glucagon-secreting cell Anatomy 0.000 title claims 19
- 210000002660 insulin-secreting cell Anatomy 0.000 title claims 19
- 239000000203 mixture Substances 0.000 title claims 15
- 206010012601 diabetes mellitus Diseases 0.000 title claims 13
- 238000000034 method Methods 0.000 title claims 12
- 210000004923 pancreatic tissue Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 18
- 230000003248 secreting effect Effects 0.000 claims 14
- 238000013188 needle biopsy Methods 0.000 claims 5
- 210000000496 pancreas Anatomy 0.000 claims 5
- 230000001902 propagating effect Effects 0.000 claims 5
- 102000051325 Glucagon Human genes 0.000 claims 4
- 108060003199 Glucagon Proteins 0.000 claims 4
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 4
- 206010033645 Pancreatitis Diseases 0.000 claims 4
- 102100040120 Prominin-1 Human genes 0.000 claims 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 4
- 229960004666 glucagon Drugs 0.000 claims 4
- 208000016222 Pancreatic disease Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 210000004153 islets of langerhan Anatomy 0.000 claims 2
- 208000024691 pancreas disease Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (20)
1.Type 1 diabetic donor pancreas, a pancreatitis donor pancreas, or a combination thereof.
2. The composition of claim 1, wherein at least about 50% of the insulin and glucagon secreting cell population expresses CD133, glucagon, and insulin.
3. The composition of claim 1, wherein about 50% to about 100% of insulin and glucagon secreting cell population expresses CD133, glucagon, and insulin..
4. The composition of claim 1, wherein the insulin and glucagon secreting cell population comprises from about 1.2x 10 cells to about 25 x 10 cells per kg of body weight in a human recipient.
5. The composition of claim 1, wherein the non-insulin secreting pancreatic cells are collected via needle biopsy are obtained from a Type 1 diabetic donor pancreas.
6. The composition of claim 1, wherein the non-insulin secreting pancreatic cells collected via needle biopsy are obtained from a pancreatitis donor pancreas.
7. The composition of claim 1, wherein the non-insulin secreting pancreatic cells are isogenic, allogenic, or a combination thereof.
8. The composition according to any one of the previous claims for use in treating a pancreatic disorder, wherein the use comprises administering to a subject in need thereof a therapeutically effective amount of the composition, wherein the pancreatic disorder comprises Type 1 diabetes, pancreatitis, or a combination thereof.
9. The composition of claim 8, wherein said administering comprises delivering to the subject the therapeutically effective amount of the composition via one or more of an injection, infusion, omental or peritoneal pouch, surgical implantation, or via packaging the composition as part of a device to a target site in the subject.
10. A method for preparing a composition comprising an insulin and glucagon secreting cell population, which comprises: treating in vitro a population of non-insulin secreting Type 1 diabetic pancreatic cells with an islet cell culture medium comprising a base medium and an effective amount of a polypeptide comprising an amino acid sequence set forth in SEQ ID NO. 1 or 2.
11. The method of claim 10, wherein the treating further comprises differentiating the population of non-insulin secreting Type 1 diabetic pancreatic cells and propagating the insulin and glucagon secreting cell population.
12. The method of claim 10, wherein the treating further comprises differentiating the population of non-insulin secreting Type 1 diabetic pancreatic cells and propagating the insulin and glucagon secreting cell population, wherein the insulin and glucagon secreting cell population at least about 50% of insulin and glucagon secreting cell population expresses CD133, glucagon, and insulin.
13. The method of claim 10, wherein the treating further comprises differentiating the population of non-insulin secreting Type 1 diabetic pancreatic cells and propagating the insulin and glucagon secreting cell population, wherein the insulin and glucagon secreting cell population about 50% to about 100% of insulin and glucagon secreting cell population expresses CD133, glucagon, and insulin.
14. The method of claim 10, wherein the treating further comprises differentiating the population of non-insulin secreting Type 1 diabetic pancreatic cells and propagating the insulin and glucagon secreting cell population, wherein the insulin and glucagon secreting cell population comprises from about 3 x 10 cells to about 25 x 10 cells per kg of body weight in a human recipient.
15. The method of claim 10 further comprising extracting the population of non- insulin secreting Type 1 diabetic pancreatic cells from a donor.
16. The method of claim 10 further comprising extracting the population of non- insulin secreting Type 1 diabetic pancreatic cells from a donor via needle biopsy.
17. The method of claim 10 further comprising extracting the population of non- insulin secreting Type 1 diabetic pancreatic cells from an isogenic donor, and allogenic donor, or a combination thereof.
18. The method of claim 10, wherein the islet cell culture medium comprises the polypeptide in amount that ranges from about 3 µg/mL to about 20 µg/mL.
19. The method of claim 10, wherein the treating further comprises differentiating the population of non-insulin secreting Type 1 diabetic pancreatic cells and propagating the insulin and glucagon secreting cell population to obtain a therapeutically amount of the insulin and glucagon secreting cell population and the method further comprises administering to a subject in need thereof the therapeutically effective amount of the insulin and glucagon secreting cell population.
20. A composition comprising an insulin and glucagon secreting cell population generated from non-insulin secreting pancreatic cells collected via needle biopsy from a Type 1 diabetic donor pancreas for use in the treatment of Type 1 diabetes, pancreatitis, or a combination thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247252P | 2021-09-22 | 2021-09-22 | |
| US202263337137P | 2022-05-01 | 2022-05-01 | |
| PCT/US2022/044024 WO2023049079A2 (en) | 2021-09-22 | 2022-09-19 | Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311468A true IL311468A (en) | 2024-05-01 |
Family
ID=85721374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311468A IL311468A (en) | 2021-09-22 | 2022-09-19 | Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4404945A2 (en) |
| JP (1) | JP2024532985A (en) |
| KR (1) | KR20240073018A (en) |
| AU (1) | AU2022349361A1 (en) |
| CA (1) | CA3231258A1 (en) |
| IL (1) | IL311468A (en) |
| MX (1) | MX2024002534A (en) |
| WO (1) | WO2023049079A2 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR311601A0 (en) * | 2001-02-15 | 2001-03-08 | Adp Pharmaceutical Pty Limited | Matrix gene expression in chondrogenesis |
| EP1745154B1 (en) * | 2004-05-07 | 2012-08-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
| RU2607380C2 (en) * | 2010-03-01 | 2017-01-10 | Янссен Байотек, Инк. | Methods of purifying cells, derived from pluripotent stem cells |
| US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| EP3810174A4 (en) * | 2018-06-25 | 2022-05-11 | Imagine Pharma, Llc | Compositions and methods for propagating insulin-producing islet cells and therapeutic uses thereof |
-
2022
- 2022-09-19 AU AU2022349361A patent/AU2022349361A1/en active Pending
- 2022-09-19 IL IL311468A patent/IL311468A/en unknown
- 2022-09-19 MX MX2024002534A patent/MX2024002534A/en unknown
- 2022-09-19 CA CA3231258A patent/CA3231258A1/en active Pending
- 2022-09-19 EP EP22873465.3A patent/EP4404945A2/en active Pending
- 2022-09-19 JP JP2023532710A patent/JP2024532985A/en active Pending
- 2022-09-19 KR KR1020247009267A patent/KR20240073018A/en unknown
- 2022-09-19 WO PCT/US2022/044024 patent/WO2023049079A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3231258A1 (en) | 2023-03-30 |
| JP2024532985A (en) | 2024-09-12 |
| EP4404945A2 (en) | 2024-07-31 |
| KR20240073018A (en) | 2024-05-24 |
| WO2023049079A2 (en) | 2023-03-30 |
| MX2024002534A (en) | 2024-07-23 |
| AU2022349361A1 (en) | 2024-03-07 |
| WO2023049079A3 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Efficient angiogenesis-based diabetic wound healing/skin reconstruction through bioactive antibacterial adhesive ultraviolet shielding nanodressing with exosome release | |
| JP2014518217A5 (en) | ||
| Xu et al. | Optimization of timing and times for administration of atorvastatin-pretreated mesenchymal stem cells in a preclinical model of acute myocardial infarction | |
| Yin et al. | VEGF-conjugated alginate hydrogel prompt angiogenesis and improve pancreatic islet engraftment and function in type 1 diabetes | |
| JP2009514950A5 (en) | ||
| JP2016033147A (en) | Compositions and methods for cardiac tissue protection and regeneration | |
| KR20130009651A (en) | Cell therapy product for cartilage damage comprising collagen, hyaluronic acid derivative and mammalian umbilical cord-derived stem cells | |
| Menasché | Cardiac cell therapy: current status, challenges and perspectives | |
| TW200914039A (en) | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form | |
| KR102473820B1 (en) | injectable composition comprising mesenchymal stem cells-hydrogel and preparation, freeze and thaw method thereof | |
| Souza et al. | Islet transplantation in rodents: do encapsulated islets really work? | |
| Balaji et al. | Injectable antioxidant and oxygen-releasing lignin composites to promote wound healing | |
| WO2023184818A1 (en) | Use of mitoxantrone in preparing medicament for preventing or treating acute graft-versus-host disease | |
| Saudek et al. | Transplantation of pancreatic islets into the omentum using a biocompatible plasma-thrombin gel: first experience at the institute for clinical and experimental medicine in Prague | |
| IL311468A (en) | Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof | |
| RU2012137126A (en) | STRAIN OF MICROORGANISM Esherichia-PRODUCER pDNA pCMV-VEGF165, METHOD FOR STORING PDNA, PHARMACEUTICAL COMPOSITION FOR STIMULING ANGIOGENESIS AND METHOD OF ITS APPLICATION | |
| Schwenter et al. | Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions | |
| Okada et al. | Cytoplasm-responsive delivery systems for siRNA using cell-penetrating peptide nanomicelles | |
| CA3216694A1 (en) | Vasoactive intestinal peptide (vip) receptor antagonists | |
| Xue et al. | Advances in single-cell nanoencapsulation and applications in diseases | |
| CN107446024A (en) | It is a kind of can antagonism DDX3 protein rna binding activity polypeptide DIP 13 and its application | |
| Lavallard et al. | Human amniotic epithelial cells integrated into the islet heterospheroids enhance insulin secretion and protect islet cells from hypoxic injury | |
| Singh et al. | Transplanting fragments of diabetic pancreas into activated omentum gives rise to new insulin producing cells | |
| CN108703977A (en) | Application of cyanobacteria and membrane-outer vesicle thereof in preparation of medicine for treating diseases | |
| KR20170026254A (en) | Composition for insulin secreting cell transplantation and method for preparing the same |